Adma Biologics investors were reminded to contact BFA Law regarding a filed securities fraud class action lawsuit aimed at recovering investment losses. The update contains no new alleged facts or case developments, but highlights ongoing litigation risk for the company.
Adma Biologics investors were reminded to contact BFA Law regarding a filed securities fraud class action lawsuit aimed at recovering investment losses. The update contains no new alleged facts or case developments, but highlights ongoing litigation risk for the company.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
